April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
ROCK Inhibitor Regulates the G1-S Progression of Corneal Endothelial Cells
Author Affiliations & Notes
  • Naoki Okumura
    Ophthalmology,
    Kyoto Prefectural University Med, Kyoto, Japan
  • Noriko Koizumi
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Kenta Yamasaki
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Morio Ueno
    Ophthalmology,
    Kyoto Prefectural University Med, Kyoto, Japan
  • Yuji Sakamoto
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Yoshihiro Sowa
    Molecular-Targeting Cancer Prevention,
    Kyoto Prefectural University Med, Kyoto, Japan
  • Toshiyuki Sakai
    Molecular-Targeting Cancer Prevention,
    Kyoto Prefectural University Med, Kyoto, Japan
  • Junji Hamuro
    Ophthalmology,
    Kyoto Prefectural University Med, Kyoto, Japan
  • Shigeru Kinoshita
    Ophthalmology,
    Kyoto Prefectural University Med, Kyoto, Japan
  • Footnotes
    Commercial Relationships  Naoki Okumura, None; Noriko Koizumi, None; Kenta Yamasaki, None; Morio Ueno, None; Yuji Sakamoto, None; Yoshihiro Sowa, None; Toshiyuki Sakai, None; Junji Hamuro, None; Shigeru Kinoshita, None
  • Footnotes
    Support  The Adaptable and Seamless Technology Transfer Program through Target-driven R & D (grant number: AS2111180G) from the Japan Science and Technology Agency
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6594. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Naoki Okumura, Noriko Koizumi, Kenta Yamasaki, Morio Ueno, Yuji Sakamoto, Yoshihiro Sowa, Toshiyuki Sakai, Junji Hamuro, Shigeru Kinoshita; ROCK Inhibitor Regulates the G1-S Progression of Corneal Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6594.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We previously demonstrated that the Rho kinase (ROCK) inhibitor Y-27632 promotes wound healing of corneal endothelial cells (CECs) in a primate model and showed the possibility of the clinical application for humans who are in a corneal endothelial deficient condition (ARVO, 2009). This current study was conducted to demonstrate the effect of Y-27632 on the cell cycle of corneal endothelial cells in vitro.

Methods: : CECs of cynomolgus monkeys were cultured and were seeded at a density of 2.5×104/cm2. The culture medium was then replaced with fresh medium containing 10 µM of Y-27632 at 24 hours after cell seeding. Culture medium without Y-27632 was used for the control. The phosphorylation of Rb protein, which regulates G1-S progression, was examined by Western blot assay at 6, 12, and 24 hours after treatment with Y-27632. In addition, labeling assay using BrdU, which is a marker of S phase, was performed at 48 hours after treatment.

Results: : Western blot assay demonstrated that phosphorylation of Rb protein at serine 807/811 and serine 780 was promoted in the Y-27632-treated CECs compared to the control cells at 12 and 24 hours. BrdU-labeling assay of 48 hours showed a statistically higher proportion of BrdU-positive CECs among cell populations cultured with Y-27632 compared to among control cells (32.4±4.2% and 18.8±0.7%, respectively; p<0.01).

Conclusions: : The findings of this study demonstrate that ROCK inhibitor Y-27632 promotes cell proliferation of corneal endothelial cells through G1-S progression via the phosphorylation of Rb protein.

Keywords: cornea: endothelium • drug toxicity/drug effects • proliferation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×